Hims & Hers Week in Review: Q3 Miss, Weak Q4 Outlook, Huberman Joins Board

Hims & Hers Health Inc. (NYSE:HIMS) had a busy week that included third-quarter results that missed estimates, a new board member in Andrew Huberman and a round of analyst price target changes.

• Hims & Hers stock is gaining positive traction. Why are HIMS shares climbing?

Hims & Hers Misses Estimates, Revenue Rises 49%

Hims & Hers reported a third-quarter loss of 14 cents per share, versus the consensus estimate of earnings of 8 cents. It reported revenue of $890.373 million, up 49% from a year earlier, missing the consensus estimate of $892.888 million. Subscribers grew to nearly 2.8 million, up 13% from a year earlier. Domestic revenue rose 21%, and international revenue rose more than 300%. Chief Financial Officer Yemi Okupe said the company intentionally paced marketing spend ahead of several planned platform expansions in the fourth quarter.

Hims & Hers Narrows 2026 Revenue Outlook, Guides Q4 Below Estimates

Hims & Hers narrowed its fiscal 2026 revenue guidance to $3.13 billion to $3.15 billion from $3.10 billion to $3.30 billion, versus the consensus estimate of $3.209 billion. For the fourth quarter, it expects revenue of $875 million to $895 million, versus the consensus estimate of $953.446 million.

Neuroscientist Andrew Huberman Joins the Board

On Nov. 9, Hims & Hers appointed Andrew Huberman, Ph.D., a Stanford neuroscientist and host of the Huberman Lab podcast, to its board of directors. He will also serve as a scientific and brand marketing advisor and provide additional marketing support through his podcast. "Andrew Huberman has done more than almost anyone to make rigorous science accessible and actionable for millions of people," said Andrew Dudum, Hims & Hers’ CEO and co-founder.

Analysts Cut Targets After the Report, While Evercore Raises Its Own

On Nov. 10, Jefferies kept a Hold rating and lowered its target to $24, and Morgan Stanley kept an Equal-Weight rating and lowered its target to $25. Evercore ISI kept an In-Line rating and raised its target to $27. Needham earlier lowered its Buy-rated target to $32 from $42. The stock carries a Hold rating with an average price target of $30.67.

Hims & Hers Stock Edges Higher

HIMS Price Action: At the time of publication, Hims and Hers shares are trading 1.62% higher at $19.44, according to data from Benzinga Pro.

Image via Shutterstock